Wells Fargo downgraded iTeos Therapeutics (ITOS) to Equal Weight from Overweight with a $12 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics Stock (ITOS) Booms 24% as it Winds Down and Sells Cancer Treatments
- iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision
- iTeos Therapeutics downgraded to Neutral from Outperform at Wedbush
- iTeos Therapeutics Announces Strategic Wind Down Plan
- iTeos Therapeutics announces intention to wind down operations
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue